The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Friday broker round-up UPDATE

Fri, 07th Mar 2014 09:39

AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation.Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to reduce with a target price of 1234p.Atkins (WS): JP Morgan raises target price from 1466p to 1619p and retains its overweight rating.Aureus Mining: RBC Capital lowers target price from 70p to 60p and reiterates its outperform rating.Aviva: JP Morgan raises target price from 491p to 528p and keeps an overweight rating. Barclays raises target price from 380p to 415p, but stays with its underweight rating.Avocet Mining: Investec lowers target price from 12.1p to 11.8p and reiterates a hold recommendation.Balfour Beatty: Investec places both its target price (prev.: 170p) and its sell recommendation under review.Betfair Group: JP Morgan increases target price from 990p to 1100p and keeps a neutral rating. Barcalys takes target price from 1120p to 1245.6p maintaining an overweight rating.BP: UBS moves target price from 500p to 515p and retains a neutral rating.Cranswick: Panmure Gordon ups target price from 1300p to 1330p and keeps a hold recommendation.Faroe Petroleum: Credit Suisse shifts target price from 119p to 125p, while staying with its underperform rating.Fresnillo: Citi raises target price from 781p to 847p, but still recommends selling.Goals Soccer Centres: Panmure Gordon downgrades from buy to hold with a target price of 213p.HSBC Holdings: Goldman Sachs reduces target price from 900p to 740p and downgrades from strong buy to buy.Hunting: Deutsche Bank raises target price from 900p to 950p and maintains a buy recommendation. Barclays cuts target price from 1100p to 1050p, while leaving its overweight rating unaltered.Imagination Technologies Group: RBC Capital lowers target price from 130p to 120p and retains an underperform rating. JP Morgan reduces target price from 425p to 210p, while leaving its overweight rating unaltered. Berenberg cuts target price from 210p to 160p reiterating its sell recommendation. Credit Suisse cuts target price from 175p to 130p and stays with its underperform rating.IMI: JP Morgan lowers target price from 1670p to 1655p and keeps an overweight rating. Barclays cuts target price from 1490p to 1450p and leaves its equal-weight rating unchanged.Intu Properties: Goldman Sachs lowers target price to 300p and downgrades to sell.Jardine Lloyd Thompson: Investec moves target price from 1130p to 1170p and retains an add rating.Johnson Service Group: Investec ups target price from 52p to 70p and maintains its buy recommendation.Kazakhmys: Jefferies takes target price from 250p to 310p and stays with its hold recommendation.London Mining: JP Morgan lowers target price from 170p to 160p and retains an overweight rating.National Express: RBC Capital increases target price from 290p to 340p and retains its outperform rating.Novae Group: Westhouse Securities raises target price from 580p to 640p and upgrades from neutral to buy.Rightmove: Westhouse Securities raises target price from 2570p to 2700p and keeps a neutral rating.Royal Dutch Shell: JP Morgan ups target price from 2250p to 2270p maintaining a neutral rating.Royal Mail: JP Morgan takes target price from 700p to 765p and keeps an overweight rating.Schroders: JP Morgan increases target price from 2802p to 2946p and reiterates an overweight rating. Barclays ups target price from 3010p to 3075p maintaining its overweight rating.Spirax-Sarco Engineering: Investec places both its target price (prev.: 3425p) and its buy recommendation under review. Numis downgrades to hold with a target price of 3200p.Standard Chartered: Deutsche Bank reduces target price from 1410p to 1360p, while leaving its hold recommendation unchanged.Stratex International: Northland lowers target price from 12.8p to 10.9p and keeps a buy recommendation.Taylor Wimpey: Barclays shifts target price from 156.5p to 160.1p and maintains an overweight rating.Verona Pharma: N+1 Singer initiates with a target price of 5.1p and a buy recommendation.
More News
13 Jan 2020 11:08

Verona Pharma shares surge after results from latest study

(Sharecast News) - Respiratory disease-focussed biopharmaceuticals company Verona Pharma announced positive top-line data from a four week, 416 patient phase 2b dose-ranging study evaluating nebulised ensifentrine or placebo as an add-on treatment to 'Spiriva Respimat', or tiotropium, which is a long acting anti-muscarinic bronchodilator, in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).

Read more
13 Jan 2020 10:34

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

UK WINNERS & LOSERS SUMMARY: Spirent Up After Lifting Profit Guidance

Read more
13 Jan 2020 07:56

Verona Pharma Says Ensifentrine Study Shows Positive Results

Verona Pharma Says Ensifentrine Study Shows Positive Results

Read more
5 Nov 2019 11:29

Verona Pharma losses widen as it pours resources into ensifentrine

(Sharecast News) - Biopharmaceutical company Verona Pharma updated the market on its operations and finances for the three and nine months ended 30 September on Tuesday, highlighting positive results from the second part of its phase 2 study of the dry powder inhaler formulation of 'ensifentrine' in chronic obstructive pulmonary disorder (COPD), delivered by handheld inhaler over one week of twice-daily treatment.

Read more
5 Nov 2019 10:38

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

UK WINNERS & LOSERS SUMMARY: AB Foods Rises As Primark Adds US Stores

Read more
5 Nov 2019 10:15

Verona Pharma Third Quarter Loss Widens On Research & Development

Verona Pharma Third Quarter Loss Widens On Research & Development

Read more
29 Oct 2019 15:30

Inland Homes snaps up 50% stake in Cheshunt Lakeside Development

(Sharecast News) - Inland Homes on Tuesday acquired a 50% interest in joint-venture partner Cheshunt Lakeside Developments Limited that was held by CPC Group Limited.

Read more
6 Aug 2019 12:01

Verona Pharma Loss Widens In First Half On Clinical Trial Expenses

(Alliance News) - Verona Pharma PLC on Tuesday said its loss widened in the second quarter and the first half of 2019 as it progressed on clinical trials of Ensifentrine, used for the treatment of

Read more
5 Aug 2019 10:42

WINNERS & LOSERS SUMMARY: Risk-Off Trade Sends Gold Miners Higher

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 3.1%. The Mexican gold miner rose as the price of

Read more
5 Aug 2019 09:44

Verona Pharma Shares Jump 15% On Positive Ensifentrine Study Results

(Alliance News) - Verona Pharma PLC on Monday reported positive second phase test data for a dry powder inhaler formulation of its lead development product ensifentrine.The stock was 15% in

Read more
25 Jun 2019 15:31

Verona Pharma strengthens clinical team ahead of next round of trials

(Sharecast News) - Respiratory-focussed biopharmaceutical company Verona Pharma announced two senior appointments to its clinical team on Tuesday.

Read more
29 May 2019 16:23

Director dealings: Piers Morgan's spouse ups stake in Verona Pharma

(Sharecast News) - Verona Pharma revealed on Wednesday that chief financial officer Piers Morgan's wife Kayt Morgan had acquired 33,802 ordinary shares in the AIM-listed biotechnology outfit.

Read more
7 May 2019 14:41

Verona Pharma announces next study of nebulised ensifentrine

(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a phase 2b dose-ranging study evaluating nebulised ensifentrine (RPL554) added on to a long-acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) on Tuesday.

Read more
9 Apr 2019 15:25

Verona Pharma Gets EU Patent For COPD Clinical Candidate Ensifentrine

LONDON (Alliance News) - Verona Pharma PLC on Tuesday said it secured a key patent from the European Patent Office relating to its lead development candidate, ensifentrine.The clinical that

Read more
9 Apr 2019 08:23

Verona Pharma gets another European patent on ensifentrine

(Sharecast News) - Respiratory disease-focussed clinical stage biopharmaceutical company Verona Pharma announced on Tuesday that the European Patent Office had granted an additional key patent relating to its lead development candidate, 'ensifentrine'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.